

1 Prior Fc Receptor activation primes macrophages for increased sensitivity to IgG via  
2 long term and short term mechanisms

3

4

5

6 Annalise Bond<sup>1</sup>, Sareen Fiaz<sup>1</sup>, Kirstin R Rollins<sup>1</sup>, Jazz Elaiza Q Nario<sup>1</sup>, Samuel J  
7 Rosen<sup>1</sup>, Alyssa Granados<sup>1</sup>, Maxwell Z Wilson<sup>1</sup>, Meghan A Morrissey<sup>1,2\*</sup>

8

9

10 <sup>1</sup> Molecular Cellular and Developmental Biology Department, University of California,  
11 Santa Barbara, Santa Barbara CA

12

13 <sup>2</sup> Lead contact

14 \*[morrissey@ucsb.edu](mailto:morrissey@ucsb.edu)

15

16 Keywords: macrophage, phagocytosis, Fc Receptor, IgG

17 **Summary**

18 Macrophages measure the 'eat-me' signal IgG to identify targets for phagocytosis. We  
19 wondered if prior encounters with IgG influence macrophage appetite. IgG is recognized  
20 by the Fc Receptor. To temporally control Fc Receptor activation, we engineered an Fc  
21 Receptor that is activated by light-induced oligomerization of Cry2, triggering  
22 phagocytosis. Using this tool, we demonstrate that Fc Receptor activation primes  
23 macrophages to be more sensitive to IgG in future encounters. Macrophages that have  
24 previously experienced Fc Receptor activation eat more IgG-bound cancer cells.  
25 Increased phagocytosis occurs by two discrete mechanisms – a short- and long-term  
26 priming. Long term priming requires new protein synthesis and Erk activity. Short term  
27 priming does not require new protein synthesis and correlates with an increase in Fc  
28 Receptor mobility. Our work demonstrates that IgG primes macrophages for increased  
29 phagocytosis, suggesting that therapeutic antibodies may become more effective after  
30 initial priming doses.

## 31 Introduction

32

33 Macrophages eat pathogens and infected, cancerous or dying cells via phagocytosis.  
34 To select targets for phagocytosis, macrophages measure 'eat-me' signals, like IgG  
35 antibodies. IgG is recognized by the Fc Receptor (FcR), which is phosphorylated and  
36 recruits the kinase Syk, triggering downstream signaling<sup>1,2</sup>. Therapeutic IgGs like  
37 Rituximab or Trastuzumab trigger Antibody-dependent Cellular Phagocytosis (ADCP) or  
38 Antibody-dependent Cellular Cytotoxicity (ADCC) to reduce cancer growth<sup>2-7</sup>. Even  
39 many antibodies originally designed to block the function of their target actually activate  
40 the FcR for full efficacy<sup>8,9</sup>. Given the therapeutic importance, there is substantial interest  
41 in understanding how to boost macrophage phagocytosis.

42 What affects macrophage appetite? One important parameter is how sensitive a  
43 macrophage is to 'eat-me' signals. Antibody-dependent phagocytosis requires the  
44 coordinated activation of a sufficient number of FcRs<sup>10</sup>. Targets with a subthreshold  
45 amount of IgG are not phagocytosed, despite triggering the initial steps in the  
46 phagocytosis signaling pathway<sup>10</sup>. In other macrophage signaling pathways, low levels  
47 of activating signal do not elicit any response on their own, but prime macrophages for  
48 rapid and intense response to future stimuli<sup>11</sup>. Whether subthreshold FcR signaling has  
49 any effect on macrophage appetite is not clear.

50 During an immune response or treatment with a therapeutic antibody, macrophages  
51 encounter multiple potential targets for phagocytosis sequentially, leading to bursts of  
52 FcR activation. Some encounters with antibody-opsonized cells result in phagocytosis  
53 of the entire cell<sup>3,5</sup>, but many cells do not have sufficient antibodies to trigger  
54 phagocytosis. Instead macrophages may trogocytose, or nibble, a target cell or simply  
55 ignore it<sup>12-15</sup>. In some circumstances, prior phagocytosis increases macrophage  
56 appetite<sup>16,17</sup>. In contrast, other studies demonstrated that phagocytosing several whole  
57 cancer cells reduces macrophage appetite<sup>18</sup>. There is no clear, unifying model  
58 explaining these differences, which could be dependent on the specific 'eat-me' signal  
59 presented, the time since phagocytosis, the intensity of the 'eat-me' signal, digestion of  
60 the internalized particle, or any number of other factors<sup>19</sup>.

61 To unravel how prior IgG exposure affects macrophage appetite, we need to precisely  
62 control the timing and intensity of activating specific phagocytic receptors. Delivering a  
63 temporally controlled, homogenous antibody stimuli to a population of cells is very  
64 difficult with the current tools. Because soluble IgG does not activate the FcR, IgG must  
65 be presented on antibody-bound targets. Controlling precisely the number of targets a  
66 macrophage encounters, or the timing of these encounters is very difficult and low-  
67 throughput.

68 To quantitatively control the duration and strength of FcR activation, we developed an  
69 optogenetic FcR (optoFcR). We found that prior FcR activation primes macrophages for  
70 greater responses to subsequent stimuli. Counterintuitively, low levels of optoFcR

71 activation induced stronger priming than high levels of optoFcR activation. Macrophage  
72 priming is controlled by two independent mechanisms, one short-term (<1 hour) and  
73 one long-term response (starting at 4 hours, and lasting up to 3 days). The short term  
74 response is associated with an increase in FcR mobility, accelerated initiation of  
75 phagocytosis and increased phagocytic cup formation. The long term response requires  
76 activation of Erk to drive a transcriptional response. These data suggest that  
77 macrophages can integrate signaling from previous encounters with IgG to modify the  
78 response to the next target. This study provides insight into how macrophage appetite is  
79 regulated, and may suggest strategies to enhance antibody-dependent cellular  
80 phagocytosis.

81

## 82 **Results**

83

### 84 **Optogenetic FcR recapitulates native FcR signaling for precise temporal control** 85 **over signaling**

86

87 To precisely control the temporal pattern of FcR activation across an entire field of  
88 cells, we sought to design an optogenetic FcR that could be turned on and off with light.  
89 Prior work has shown that the FcR clusters upon IgG binding. Although the FcR has no  
90 inherent kinase activity, clustering promotes phosphorylation of the intracellular  
91 Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) and phagocytosis<sup>20-22</sup>. We  
92 hypothesized that clustering may be sufficient to induce FcR activation. To test this, we  
93 designed an optoFcR construct that consists of a myristoylation sequence for  
94 membrane localization, the intracellular domain for the native FcR gamma-chain and a  
95 light activatable peptide CRY2 (Figure 1a). We selected the variant CRY2olig because it  
96 forms multimeric, rapidly reversible clusters<sup>23</sup>. Upon blue light (450nm) stimulation the  
97 optoFcR oligomerizes (Figure 1b; Video S1). Clusters dissociate when the cells are  
98 returned to the dark (Figure 1b). Clustering also results in the recruitment of the  
99 downstream effector protein Syk, suggesting that clustering is sufficient to induce FcR  
100 phosphorylation (Figure 1c,d; Video S2).

101 We next sought to determine if clustering of the optoFcR is sufficient to trigger  
102 phagocytosis. We incubated ICAM-1 conjugated beads with macrophages expressing  
103 either the optoFcR or membrane tethered mCh (mCh-CAAX) and exposed them to 15  
104 min of light stimulation (Figure 1e). ICAM-1 mediates bead binding to the macrophage,  
105 but does not trigger phagocytosis of otherwise unopsonized beads<sup>24,25</sup>. Macrophages  
106 expressing the optoFcR engulfed three times as many beads as control macrophages  
107 when stimulated with the highest intensity light and twice as many beads when  
108 stimulated with medium intensity light (Figure 1f,g; Figure S1; Video S3). Low intensity  
109 light did not activate phagocytosis. This dose response is similar to the dose response  
110 seen in IgG mediated phagocytosis (Figure S1). Together, these data demonstrate that

111 clustering of the FcR ITAM domain is sufficient to initiate phagocytosis in macrophages  
112 without a specific 'eat-me' signal.

113

### 114 **Prior FcR activation enhances phagocytosis of IgG coated beads.**

115

116 With the ability to temporally control FcR activation in bone marrow-derived  
117 macrophages, we next sought to determine if prior FcR activation influences phagocytic  
118 ability. We stimulated macrophages with low intensity blue light to activate the optoFcR  
119 for 15 minutes which is around the same timescale that a macrophage interacts with a  
120 phagocytic target. We then waited 1 or 12 hours before adding IgG opsonized beads,  
121 which is sufficient time for the optoFcR to completely decluster. Then we measured the  
122 number of beads engulfed per cell using microscopy (Figure 2a). We found that prior  
123 optoFcR activation increased the amount of eating roughly 2-fold compared to cells that  
124 either did not receive prior light stimulation or did not express the optoFcR (Figure 2b).  
125 This demonstrates that prior FcR activation primes macrophages to respond to future  
126 IgG.

127 Next, we systematically varied the light intensity and stimulation time used to activate  
128 the optoFcR as well as the delay between activating the optoFcR and measuring  
129 phagocytosis of IgG coated beads. In all cases, we found that low doses of light, and  
130 thus less FcR activity, led to the highest macrophage priming (Figure S2). The amount  
131 of light that best primed macrophages was not sufficient to activate phagocytosis on its  
132 own (Figure 1h). This suggests that a sub-threshold level of FcR activation, not  
133 sufficient to activate phagocytosis, primes macrophages for future encounters with IgG.

134 We then wanted to know if we could induce macrophage priming using IgG and the  
135 endogenous FcR. Based on our data from the optoFcR, we predicted that a low level of  
136 IgG exposure would enhance phagocytosis of a second dose of IgG-coated beads. To  
137 test this, we preincubated macrophages with beads containing an IgG density that did  
138 not activate phagocytosis (Figure S1) or unopsonized beads. We then extensively  
139 washed the macrophages to remove these beads and added a second color of IgG-  
140 bound beads (Figure 2c). We found that macrophages preincubated with IgG-coated  
141 beads phagocytosed more than macrophages pre-incubated with unopsonized beads  
142 when the second dose was above the threshold for inducing phagocytosis (Figure 2d).  
143 This suggests that the native IgG and FcR system primes macrophages like the  
144 optoFcR system.

145

### 146 **Prior FcR activation specifically enhances phagocytosis of IgG coated beads, not 147 phosphatidylserine or unopsonized beads.**

148

149 We next wanted to know if prior FcR activation specifically primed macrophages to  
150 phagocytose IgG-coated targets or if it broadly enhanced phagocytosis. We first

151 determined if prior optoFcR activation increased non-specific phagocytosis of  
152 unopsonized targets. Primed macrophages did not phagocytose more unopsonized  
153 beads than control macrophages (Figure 2e). We then determined if prior optoFcR  
154 activation increased efferocytosis, the engulfment of apoptotic cells. The molecular  
155 regulators of efferocytosis partially overlap with antibody-dependent phagocytosis, but  
156 the processes require some unique signaling pathways including different ‘eat-me’  
157 signal receptors<sup>26</sup>. By integrating phosphatidylserine (PS), an efferocytic ‘eat-me’ signal,  
158 into the lipid mixture on our silica bead targets, we can recapitulate apoptotic corpse  
159 engulfment *in vitro*<sup>27</sup>. We incubated PS-coated beads with macrophages at 1 and 12  
160 hours post light stimulation and measured the amount of eating. There was no change  
161 in the amount of eating at either timepoint (Figure 2f). These data suggest that prior FcR  
162 activation primes macrophages to specifically react to IgG. This also suggests that the  
163 molecular regulators of priming are unique to FcR signaling, rather than in one of the  
164 pathways shared by efferocytosis and antibody-dependent phagocytosis.

165 We then investigated if prior FcR stimulation changed macrophage sensitivity for IgG,  
166 lowering the threshold of IgG required for initiating phagocytosis. Alternatively, priming  
167 could increase macrophage capacity, the maximum number of targets each  
168 macrophage can engulf. To do this, we added beads with various concentrations of IgG  
169 to BMDMs and calculated the phagocytic index (Figure S2). Primed macrophages show  
170 enhanced eating of beads with low concentration of IgG. The total capacity for  
171 phagocytosis is not significantly changed in primed macrophages. This indicates that  
172 priming primarily alters macrophage sensitivity to low levels of IgG, rather than overall  
173 capacity for phagocytosis.

174

### 175 **Primed macrophages phagocytose more antibody opsonized cancer cells.**

176

177 We next sought to determine if primed macrophages can increase whole cell eating of  
178 opsonized cancer cell targets. In addition to phagocytosis, macrophages often  
179 trogocytose or nibble target cells, stripping the cancer cells of target antigen without  
180 killing them<sup>15</sup>. Prior clinical studies have shown that the anti-CD20 therapeutic antibody  
181 (rituximab) is most effective when administered more frequently at a low dose, which  
182 minimizes antigen shaving<sup>28</sup>. Given our results, we hypothesized that prior FcR  
183 activation might also enhance phagocytosis of cancer cells. We first measured  
184 phagocytosis of Raji B cells incubated with increasing concentrations of anti-CD20  
185 antibody to find an antibody concentration where we could detect a change in  
186 macrophage sensitivity (Figure S3). To measure both the amount of whole cell  
187 phagocytosis and trogocytosis, we incubated IgG opsonized Raji cell targets with  
188 primed or unprimed optoFcR-expressing BMDMs and analyzed the cells with timelapse  
189 microscopy (Figure 3a-b; Video S4-6). We found that the number of Raji cells  
190 phagocytosed, and the percent of phagocytic macrophages increased in primed

191 macrophages (Figure 3c-d). The percentage of primed macrophages that trogocytosed  
192 was not significantly increased compared to unprimed macrophages (Figure 3e). This  
193 suggests that primed macrophages are better at phagocytosing antibody-opsonized  
194 cancer cells.

195

### 196 **Macrophage priming occurs through a short-term and long-term mechanism.**

197

198 We next sought to determine the molecular mechanism for enhanced phagocytosis  
199 after FcR activation. We observed enhanced phagocytosis at both 1 hour and 12 hours  
200 after optoFcR stimulation (Figure 2b). While 12 hours post-stimulation is likely enough  
201 time for changes in transcription or translation to affect macrophage phenotypes, 1 hour  
202 is likely too short for this mechanism. We decided to carefully assay when macrophage  
203 priming occurred. To do this we activated the optoFcR and varied the time before  
204 presenting a second stimulus of IgG coated beads and measuring phagocytosis. We  
205 saw robust priming occurring in two discrete waves: a short-term response that peaks  
206 around 1 hour after FcR activation, and a long-term response that begins at 4 hours  
207 after FcR activation and persists for at least 24 hours (Figure 4a).

208 As the long-term priming following optoFcR activation persists for at least 72 hours,  
209 we speculated that this response requires *de novo* protein production rather than a  
210 more transient post-translational modification mechanism. We evaluated priming in  
211 macrophages treated with cycloheximide (CHX) and actinomycin D (AD) to inhibit  
212 translation and transcription respectively. Treatment with either CHX or AD significantly  
213 reduced phagocytosis in primed macrophages compared to DMSO treated control  
214 macrophages at 4 and 6 hours post light stimulation (Figure 4b). This suggests that *de*  
215 *nov*o mRNA and protein synthesis is required for a long-term memory response.  
216 Blocking new protein synthesis did not significantly reduce priming at 1 hour post  
217 stimulation, suggesting that short-term memory is not reliant on new protein production  
218 (Figure 4b). Overall this suggests that there are two mechanisms for macrophage  
219 priming – one that operates on a short timescale and does not require synthesis of new  
220 proteins, and one that operates on a long time scale and requires changes in gene  
221 expression.

222

### 223 **Erk activation is required for long-term priming.**

224

225 Because long term priming requires new protein production, we sought to dissect  
226 which transcriptional programs were being executed by the macrophages. Erk, a  
227 nuclear kinase, functions downstream of the FcR and regulates the macrophage dose  
228 dependent response to LPS as well as many other immune signaling pathways<sup>11</sup>. To  
229 determine if Erk contributes to macrophage priming, we used PD0325901 to block Erk  
230 activity. We then stimulated the optoFcR for 15 minutes, waited 1 or 12 hours, and  
231 measured phagocytosis of IgG-coated beads. Inhibiting Erk signaling blocked long-term

232 memory with no effect on short-term memory (Figure 4c). These results indicate that  
233 long-term priming requires a transcriptional response mediated by Erk activation.

234

### 235 **Initiation of engulfment proceeds faster and has a higher success rate in primed** 236 **macrophages.**

237

238 Having demonstrated that short-term priming does not require new protein synthesis  
239 like long-term priming, we sought to determine the mechanism for short term priming.  
240 To do this, we first wanted to isolate which step in the phagocytic process was  
241 enhanced by prior sub-threshold activation of the FcR. We quantified the kinetics of  
242 engulfment using live cell imaging, breaking the process of phagocytosis into three  
243 steps: target binding, initiation of phagocytosis, and completion<sup>21</sup> (Figure 5a,b; Video  
244 S7). We then quantified the time between each step in primed and unprimed  
245 macrophages, and the percent of bead contacts that successfully progressed from one  
246 step to the next without membrane retraction and target release. Primed macrophages  
247 were more likely to initiate phagocytosis of bound beads, and the time between bead  
248 binding and initiation was less (Figure 5c,d). In contrast, after initiation the chance of  
249 successfully completing phagocytosis and the speed of phagocytosis were the same in  
250 primed and unprimed macrophages (Figure 5e,f). Overall, the percent of bead contacts  
251 that result in successful phagocytic events is significantly increased in primed  
252 macrophages (Figure 5g). Stimulated control macrophages that do not express the  
253 optoFcR did not show a difference in any measure of phagocytosis compared to  
254 unstimulated macrophages (Figure S4). These data indicate that prior sub-threshold  
255 FcR activation primes macrophages for faster target recognition and more frequent  
256 signal initiation, implicating early phagocytic machinery.

257

### 258 **Priming is associated with enhanced FcR mobility.**

259

260 As initiation of phagocytosis is faster in primed macrophages, and our prior data  
261 indicated that the molecular regulator of priming was specific to the FcR pathway, we  
262 decided to look at FcR mobility. Clustering of IgG, and subsequently FcR, increases the  
263 frequency and speed of initiating phagocytosis but not the speed of cup closure, similar  
264 to the phenotype we observed in our phagocytosis kinetics analysis<sup>21</sup>. FcR cluster  
265 formation and subsequent activation is dependent on the lateral mobility of FcRs, which  
266 is constrained by a heterogeneous F-actin 'fence' and other mechanisms<sup>29-32</sup>. Increased  
267 FcR mobility correlates with increased binding of IgG-coated targets and  
268 phagocytosis<sup>29,31</sup>. We hypothesized that primed macrophages may have higher FcR  
269 mobility, which could explain the increased speed and frequency of initiating  
270 phagocytosis. To determine if optoFcR priming increases receptor mobility, we tracked  
271 single FcR molecules on optoFcR primed and unprimed cells (Figure 6a). On average,  
272 the FcR molecules on primed macrophages had a higher mean jump distance (MJD;



273 average distance traveled between frames) than on unprimed macrophages (Figure  
274 6b). Graphing the MJD of individual tracks, primed macrophages had a multi-modal  
275 distribution of track MJDs, suggesting there may be a more mobile population in the  
276 primed macrophages (Figure 6c).

277 Previous studies have described FcR motion as free or confined<sup>29,31</sup>. Confined FcRs  
278 have limited mobility and may not be available to form signaling microclusters required  
279 for phagocytosis. To see if primed macrophages had more free FcRs, we categorized  
280 FcR tracks by motion type using a moment scaling spectrum analysis. Consistent with  
281 previous studies, we found a population of confined Fc Receptors that were restricted to  
282 small microdomains or 'corals' within the membrane (Figure 6d,e). This population was  
283 decreased in primed macrophages, suggesting that more FcRs may be available to join  
284 signaling microclusters. In addition, the average diffusion coefficient, indicative of how  
285 far each receptor travels, was significantly higher in primed macrophages (Figure 6f).  
286 Overall, this data suggests that FcRs are more mobile on primed macrophages, which  
287 may increase formation of FcR signaling clusters and the probability of initiating  
288 phagocytosis.

289

## 290 Discussion

291

292 Our work suggests that the macrophage response to IgG integrates information from  
293 sequential encounters with IgG coated targets. Prior FcR activation makes  
294 macrophages more likely to phagocytose an IgG-coated target. This enhanced  
295 phagocytosis correlates with an increase in FcR mobility in the short term. Long term  
296 priming requires Erk signaling and transcription of new proteins.

297 Clustering of the FcR has previously been linked to its activation and enhanced  
298 phagocytosis<sup>21,22,33,34</sup>. We recapitulate this clustering using an optogenetic method and  
299 find that clustering of the optogenetic FcR is sufficient to drive Syk recruitment, which is  
300 indicative of phosphorylation of the intracellular Immunoreceptor Tyrosine-based  
301 Activation Motifs (ITAMs). The FcR has no inherent kinase activity, so why does  
302 clustering promote receptor activation? ITAM phosphorylation is controlled by the  
303 opposing actions of Src family kinases, which favor activation, and transmembrane  
304 phosphatases like CD45 that deactivate the receptor<sup>1</sup>. Prior work has shown that  
305 particle binding drives CD45 exclusion from the phagocytic synapse because the bulky  
306 extracellular domain is sterically excluded from the tight membrane-membrane  
307 interface<sup>35-38</sup>. This allows Src family kinases to dominate, tipping the kinase-  
308 phosphatase balance in favor of FcR activation<sup>39</sup>. Our prior work has shown that FcR  
309 clustering enhances ITAM phosphorylation independent of avidity effects that would  
310 increase receptor binding to the target<sup>21</sup>. This may be mediated by the formation of lipid  
311 ordered domains that segregate kinases and phosphatases, favoring immune receptor  
312 activation<sup>40,41</sup>. The optoFcR is tethered to the membrane via a myristoylation motif,

313 favoring inclusion in lipid ordered domains, which may promote activation by Src family  
314 kinases and segregation from CD45 without the need for particle binding. Alternatively,  
315 the geometry of the clustered intracellular FcR domains may promote activation through  
316 another mechanism.

317 In the hour following optoFcR activation, the mobility of native FcRs on the  
318 macrophage surface increases. FcR mobility is constrained by the actin cytoskeleton  
319 and actin-associated transmembrane pickets<sup>29,31,32,42</sup>. Syk kinase activation rearranges  
320 the actin cytoskeleton allowing for less constrained FcR diffusion and greater mobility<sup>31</sup>.  
321 Since the optoFcR also recruits Syk, this may underlie the change in FcR mobility in our  
322 system. Our working model is that increased FcR mobility increases the formation of  
323 receptor clusters that promote initiating and continuing phagocytosis. This could  
324 enhance macrophage sensitivity by enabling formation of signaling clusters with a lower  
325 overall IgG density.

326 Prior work has shown a critical threshold of FcR activation is required for  
327 macrophages to commit to phagocytosis<sup>10</sup>. FcR signaling that is below this threshold  
328 activates the initial steps in the phagocytic signaling pathway, including recruitment of  
329 the downstream effector kinase Syk<sup>10</sup>. Whether this low level of activation has any effect  
330 on macrophages was not clear. Our data suggests that this low level of activation may  
331 have a purpose in the macrophage, allowing the cell to prepare for future encounters  
332 with IgG-bound targets.

333 Our data show that lower levels of optoFcR stimulation prime phagocytosis better than  
334 high levels. Prior work has shown that low levels of TLR activation prime macrophages  
335 for a rapid and strong response to future stimuli, without activating an inflammatory  
336 response alone<sup>11</sup>. Our study suggests this may be true for the FcR pathway as well. The  
337 effect of high levels of FcR activation may be different because it is associated with  
338 receptor internalization, which can lead to decreased phagocytic capacity<sup>18</sup>. Previous  
339 studies have shown that phagocytosing many antibody-coated cancer cells causes  
340 macrophage 'hypophagia' or reduced phagocytosis. This suggests that the signaling  
341 consequences of successful phagocytosis and sub-threshold FcR activation may be  
342 quite different.

343 While the adaptive immune system is traditionally thought of as the source of  
344 immunological memory, a growing body of evidence shows that the innate immune  
345 system also remembers prior infections and threats. This is often called "trained  
346 immunity" and occurs via epigenetic reprogramming of myeloid cells to increase or  
347 decrease their transcriptional response to reinfection<sup>16,43,44</sup>. Trained immunity can  
348 persist for years if myeloid progenitor cells are affected. Most of the work on trained  
349 immunity has focused on a memory of pathogenic molecules or inflammatory cytokines.  
350 Our work builds on this, suggesting that FcR activation also elicits a long term molecular  
351 memory. In contrast, the short term priming we describe is distinct from prior  
352 descriptions of trained immunity since it does not involve changes in gene expression.

353 The FcR is required for the full efficacy of many cancer immunotherapies, including  
354 popular immunotherapies like PD-1 and CTLA-4 blockades<sup>9,45</sup>. Some therapies, like the  
355 anti-CD20 antibody Rituximab, heavily rely on antibody-dependent cellular phagocytosis  
356 as a mechanism for eliminating cancer cells<sup>4</sup>. Interestingly, more frequent low dose  
357 treatments of Rituximab are more effective at treating Chronic Lymphocytic Leukemia  
358 (CLL) patients than higher dose treatments<sup>28</sup>. A key reason for this dosing schedule is  
359 to mitigate antigen shaving, or trogocytosis of target antigen. Enhancing phagocytosis  
360 without increasing antigen shaving is important but difficult. Our data shows that primed  
361 macrophages are better at phagocytosing whole cancer cells, but equally likely to  
362 trogocytose. This suggests that the current dosing regimen of frequent, low doses may  
363 already benefit from the effects of macrophage priming. Additionally, monocytes  
364 expressing Chimeric Antigen Receptors that signal through the FcR intracellular  
365 signaling domain are an exciting new avenue of cancer research<sup>46-49</sup>. How can we  
366 engineer hungrier macrophages to attack cancer cells? Our studies reveal that  
367 macrophage priming could enhance phagocytosis or other anti-cancer signaling  
368 pathways in these macrophages.

369

### 370 **Acknowledgements**

371 We thank members of the Morrissey lab for critical feedback on this manuscript. This work was  
372 supported by the UCSB Academic Senate, the National Institute of General Medical Sciences of  
373 the National Institutes of Health (R35 GM146935) and the UC Cancer Research Coordinating  
374 Committee (C23CR5592) to M.A.M. and the Eunice Kennedy Shriver National Institute of Child  
375 Health and Human Development of the National Institutes of Health (R01 HD108803-01) to  
376 M.Z.W. A.B. was supported by the Karl Storz Imaging fellowship. J.E.Q.N. was supported by a  
377 supplement to C23CR5592, the EUREKA scholars program and the MARC scholars program.  
378 A.G. was supported by the MARC scholars program. Schematics were created with  
379 BioRender.com. We thank the NRI-MCDB Microscopy Facility at UCSB, especially the director  
380 Ben Lopez for providing advice.

381

### 382 **Author contributions**

383 Conceptualization, A.B., M.Z.W. and M.A.M.; Methodology, A.B., M.Z.W. and M.A.M.; Software,  
384 K.R. and S.J.R.; Validation, A.B.; Formal Analysis, A.B., S.F., K.R. and S.J.R.; Investigation,  
385 A.B, S.F., E.N. and A.G.; Resources, A.B. and M.A.M.; Writing - Original Draft, A.B. and M.A.M.;  
386 Writing - Review and Editing, A.B. and M.A.M.; Visualization, A.B.; Supervision, M.A.M.;  
387 Funding Acquisition, M.A.M.

388

### 389 **Competing interests**

390 The authors A.B., M.Z.W. and M.A.M. have filed a patent relating to this material. The authors  
391 have no other competing interests.

392

393

394 **Figure legends**

395

396 **Figure 1. Optogenetic Fc Receptor (optoFcR) controls phagocytosis.**

397 A) Schematic of optoFcR design, containing a myristoylation signal for membrane  
398 localization, the ITAM-containing intracellular domain from the FcR gamma-chain for  
399 signaling, iRFP fluorophore, and the homo-oligomerizing peptide - cryptochrome 2  
400 (CRY2olig). B) Representative images of optoFcR in bone marrow derived  
401 macrophages (BMDMs). The optoFcR starts dispersed on the membrane (T0m; n=0/22  
402 cells with visible clusters), and clusters after 15 minutes of constant high intensity light  
403 (T15m; n=21/22 cells with visible clusters). The optoFcR is declustered after 30 minutes  
404 in the dark (T45m; n=0/22 cells with visible clusters). See also supplemental movie 1. C)  
405 Representative images of downstream effector protein, SYK, colocalized with optoFcR  
406 in Raw macrophages stably expressing both the optoFcR and SYK-mNeonGreen. On  
407 the right, a line scan shows the Syk and optoFcR intensity at the position indicated by  
408 the yellow arrow in the inset. See also supplemental movie 2. D) Graph shows the  
409 Pearson's correlation coefficient for Syk and optoFcR at the cell cortex. Each data point  
410 represents a cell with an ROI drawn around a membrane region. The same ROI was  
411 used for both T0 (OFF) and T2 (ON). E) Schematic of experimental design for f-g. F)  
412 Representative images show optoFcR (green) expressing macrophages and ICAM  
413 conjugated beads visualized by atto390 in the supported lipid bilayer (magenta) before  
414 (OFF) and after (ON) 15 min of optoFcR activation with high intensity light. Internalized  
415 beads are labeled with a yellow star. See also supplemental movie 3. G) Quantification  
416 of phagocytosis in BMDMs after 15 minutes of optoFcR stimulation at low ( $5 \text{ uW/cm}^2$ ),  
417 medium ( $90 \text{ uW/cm}^2$ ), and high ( $1390 \text{ uW/cm}^2$ ) intensity light compared to control cells  
418 that do not express the optoFcR but receive the high intensity light stimulus. Both  
419 medium and high intensity light stimulate phagocytosis. Each data point represents the  
420 mean of an independent experiment. Data collected in the same replicate are denoted  
421 by symbol shape. In all graphs, bars represent the mean and SEM. \* indicates  $p < 0.05$ ,  
422 \*\*\* indicates  $p < 0.0005$  using a paired t-test (d), one way ANOVA with dunnett correction  
423 (g). Scale bars are 10  $\mu\text{m}$ . See also supplemental figure 1.

424

425 **Figure 2. Prior FcR activation specifically enhances macrophage sensitivity to**  
426 **IgG.**

427 A) Schematic of experimental design for light-induced priming. Control (mCherry-CAAX)  
428 and optoFcR expressing BMDMs were stimulated with light for 15 min. The cells were  
429 returned to the dark for either 1 or 12 hrs, then targets opsonized with 1 nM IgG were  
430 introduced. After 15 minutes of phagocytosis, beads were washed out. Cells were  
431 imaged and the number of targets phagocytosed per cell was counted. B) Quantification  
432 of experiment described in (a). OptoFcR expressing cells that received light  
433 phagocytosed significantly more than cells that did not receive light, or cells that  
434 received light but did not express the optoFcR. C) Schematic of experimental design for

435 priming macrophages with IgG beads. Wildtype BMDMs were given either beads with  
436 0.1 nM or 0 nM IgG for 15 min as a priming stimulus. Those beads were then washed  
437 out and the cells were allowed to recover for 1 hr. A second set of different color beads  
438 ligated to IgG at the indicated concentration were added and the amount of  
439 phagocytosis was determined after 15 min. D) Quantification of phagocytosis for  
440 experiment described in (c). Macrophages that were preincubated with 0.1 nM IgG-  
441 conjugated beads phagocytosed significantly more than macrophages preincubated  
442 with unopsonized beads. E) Phagocytosis of bead targets without an 'eat-me' signal.  
443 Experiment was performed as described in (a) except the beads did not contain IgG.  
444 Phagocytosis is normalized to unstimulated control cells. F) Phagocytosis of bead  
445 targets with the efferocytic 'eat-me' signal, phosphatidylserine. Phagocytosis is  
446 normalized to unstimulated control cells. Experiment was performed as described in (a)  
447 except the beads were covered in a 10% phosphatidylserine bilayer to mimic an  
448 apoptotic corpse. In all graphs, each point represents the mean of an independent  
449 experiment. Data collected in the same replicate are denoted by symbol shape. Bars  
450 represent the mean and SEM. \* indicates  $p < 0.05$ , \*\* indicates  $p < 0.005$ , \*\*\*\* indicates  
451  $p < 0.0001$  by two way anova with Sidak corrections (b), multiple T-tests with Holm-Sidak  
452 corrections (d), and unpaired t-test (e,f). See also supplemental figure 2.

453

### 454 **Figure 3. Macrophages are primed for increased cancer cell engulfment.**

455 A) Schematic of experimental design for cancer cell targets. optoFcR cells were  
456 exposed to light for 15 minutes, then returned to the dark. Raji B cells opsonized with 5  
457 ng/ml IgG were added after 12 hours, and the cancer cell-macrophage interactions were  
458 captured by timelapse microscopy. B) Representative images of optoFcR expressing  
459 macrophages completing phagocytosis and trogocytosis. Raji B cells were visualized  
460 using cell trace far red (magenta) and macrophages were visualized using optoFcR-  
461 mSc (green). Yellow arrows point to phagocytosis of a whole cancer cell and white  
462 arrows point to trogocytosis of cancer cell fragments. See also supplemental movies 4-  
463 6. C) Percent of BMDMs that engulfed a whole target cell increased with prior FcR  
464 stimulation. D) The number of whole raji cells engulfed was greater in primed  
465 macrophages. E) Percent of BMDMs that trogocytosed a raji target was not significantly  
466 different with priming. Each data point represents the mean of an independent  
467 experiment, denoted by symbol shape, and bars represent the mean and SEM.  
468 \*\* indicates  $p < 0.005$  using an unpaired t-test. See also supplemental figure 3.

469

### 470 **Figure 4. FcR mediated priming occurs via a short- and long-term mechanism.**

471 A) Phagocytosis of 1nM IgG beads added at the indicated time post 15 min low intensity  
472 light stimulation. Blue line denotes macrophages expressing the optoFcR and red  
473 denotes macrophages expressing a control mCh-CAAX. Enhanced phagocytosis occurs  
474 in two discrete peaks and lasts for at least 72 hrs. Points denote the mean of 4

475 independent replicates. Phagocytosis is normalized to unstimulated control cells. B)  
476 Macrophages were treated with Actinomycin D (AD, 10nM) or Cycloheximide (CHX,  
477 10ug/ml) to block transcription or translation respectively starting 7 hours before  
478 phagocytosis. Macrophages were stimulated with light to activate the optoFcR at 1, 4 or  
479 6 hours before phagocytosis. AD and CHX did not eliminate priming at 1 hour post-  
480 stimulation. AD and CHX eliminated the enhanced phagocytosis phenotype at 4 and 6  
481 hours post stimulation. C) Macrophages were treated with Erk inhibitor (PD0325901,  
482 0.5uM) or DMSO control for 16 hrs before measuring phagocytosis. optoFcR  
483 macrophages stimulated with light 1 hour before bead addition still showed enhanced  
484 phagocytosis. Macrophages stimulated with light 12 hours before bead addition  
485 phagocytosed the same number of beads as controls. Phagocytosis is normalized to  
486 unstimulated control cells. Each data point represents the mean of an independent  
487 experiment. Data collected in the same replicate are denoted by symbol shape. Bars  
488 represent the mean and SEM. \*indicates  $p < 0.05$ , \*\*indicates  $p < 0.005$ , \*\*\*indicates  
489  $p < 0.0005$ , \*\*\*\* indicates  $p < 0.0001$  using a two way anova with Sidak corrections (a-c).  
490

491 **Figure 5. Initiation of phagocytosis is faster and more likely in primed**  
492 **macrophages.**

493 A) optoFcR macrophages received a 15 min light stimulus 1 hour before bead addition  
494 (primed) and were compared to optoFcR macrophages that did not receive light  
495 stimulation (unprimed). Timelapse imaging was used to quantify the kinetics of  
496 phagocytosis. Schematic shows each step in phagocytosis: binding (target contact with  
497 cell), initiation (formation of the phagocytic cup), and completion (cup closure and bead  
498 internalization). Below, the schematic shows percent of macrophage-bead contacts that  
499 progress from one stage to the next for primed and unprimed macrophages. B)  
500 Representative images of each stage. Scale bar is 10 um. See also supplemental movie  
501 7. C) Percent of bead contacts that initiate phagocytosis is higher in primed  
502 macrophages. D) Time from binding to initiation in optoFcR primed macrophages is  
503 decreased compared with unprimed macrophages. E) Probability of completing  
504 phagocytosis after initiation is comparable in primed and unprimed macrophages. F)  
505 The speed of cup closure is comparable in primed and unprimed macrophages. G) The  
506 overall success rate of phagocytosis is higher in primed macrophages compared to  
507 unprimed macrophages. Each filled data point represents the mean of an independent  
508 experiment, denoted by symbol shape, and corresponding outlined data points  
509 represent individual bead times. Bars represent the mean and SEM. \*indicates  $p < 0.05$ ,  
510 \*\*indicates  $p < 0.005$ , \*\*\*indicates  $p < 0.0005$  using an unpaired t-test on the means of  
511 each replicate. See also supplemental figure 4.  
512

513 **Figure 6. Priming increases FcR mobility.**

514 A) optoFcR macrophages were primed with a 15 minute light stimulus or were not  
515 stimulated. One hour later, single FcR molecules were labeled with QDots and tracked  
516 for 60 seconds. Tracks from a representative primed and unprimed image are shown.  
517 Scale bar is 1  $\mu\text{m}$ . B) Quantification of the per image mean jump distance (MJD) of all  
518 tracks. FcRs from primed macrophages had increased MJD compared to unprimed  
519 macrophages. C) Histogram of MJD from all acquired tracks from primed and unprimed  
520 macrophages. Primed macrophages show a population of FcRs that have a greater  
521 MJD than unprimed macrophages. Histogram was smoothed in prism using a second  
522 order polynomial with 6 neighbors on each size. D) Examples of 'free' and 'confined'  
523 tracks. E) Quantification of motion type analysis shows the proportion of tracks  
524 categorized as 'free' (circles) or 'confined' (triangles) for individual images. The percent  
525 of tracks defined as 'free' increases in optoFcR expressing macrophages exposed to  
526 light is compared to optoFcR macrophages with no light exposure. F) Quantification of  
527 the per image mean diffusion coefficients. Tracks from primed macrophages have a  
528 higher diffusion coefficient compared to unprimed macrophages. Each filled data point  
529 represents the mean from a single image. Images were acquired in three separate  
530 experiments, denoted by symbol shape (b and e). Bars represent the mean and SEM.  
531 \*indicates  $p < 0.05$ , \*\*indicates  $p < 0.005$  using an unpaired t-test (b and f) or a one-way  
532 anova (e).

533 **Methods**

534 **Resource Availability**

535 **Lead Contact**

536 Further information and requests for resources and reagents should be directed to and  
537 will be fulfilled by the Lead Contact, Meghan Morrissey ([morrissey@ucsb.edu](mailto:morrissey@ucsb.edu)).

538

539 **Bone-marrow derived macrophage cell culture.**

540 Six- to ten-week-old C57BL/6 mice were sacrificed by CO<sub>2</sub> inhalation. Hips and femurs  
541 were dissected and bone marrow was harvested as described in Weischenfeldt and  
542 Porse<sup>50</sup>. Macrophage progenitors were differentiated for seven days in RPMI-1640, 10%  
543 FBS, 1% PSG supplemented with 20% L929- conditioned media. Macrophage  
544 differentiation was confirmed by flow cytometry identifying CD11b and F4/80 double  
545 positive cells. Differentiated BMDMs were used for experiments from days 7 to 11.

546

547 **Lentivirus production and infection.**

548 All constructs were expressed in BMDMs using lentiviral infection. Lentivirus was  
549 produced in HEK293T cells transfected with pMD2.G (Gift from Didier Trono, Addgene  
550 plasmid # 12259 containing the VSV-G envelope protein), pCMV-dR8.2<sup>51</sup> (Gift from Bob  
551 Weinberg, Addgene plasmid #8455), and a lentiviral backbone vector containing the  
552 construct of interest using lipofectamine LTX (Invitrogen, Catalog # 15338–100). The  
553 media was harvested 72 h post-transfection, filtered through a 0.45 µm filter (Millapore,  
554 Catalog #SLHVM33RS) and concentrated using LentiX (Takara Biosciences, Catalog  
555 #631232). Concentrated lentivirus was added to cells on day 2 of differentiation. Cells  
556 were analyzed between days 7-11.

557

558 **Optogenetic stimulation.**

559 Cells receiving low intensity light (5 uW/cm<sup>2</sup>) and medium intensity light (190 uW/cm<sup>2</sup>)  
560 were stimulated using a LITOS LED illumination plate<sup>52</sup> for 15 min. Cells receiving high  
561 intensity light were stimulated using the 488 laser at 75% laser power on a spinning disc  
562 confocal microscope for 1 s at 20 s intervals for a total of 15 m (1,389 uW/cm<sup>2</sup>). Intensity  
563 was determined using a slide power meter set to measure 450 nm light. Light used to  
564 prime cells was low intensity (5 uW/cm<sup>2</sup>) unless otherwise indicated.

565

566 **Clustering and colocalization analysis.**

567 optoFcR clustering

568 50,000 BMDMs expressing the optoFcR were plated in one well of a 96-well glass  
569 bottom MatriPlate (Brooks, Catalog # MGB096-1-2-LG-L) between 12 and 24 h prior to  
570 the experiment. Cells were then continuously imaged with high intensity light stimulation  
571 for 30 min and then imaged for another 60 min without light stimulation. Clustering was  
572 determined by the presence of visible puncta in the cells.



573

574 SYK and optoFcR colocalization

575 50,000 RAW264.7 macrophages virally infected with both the optoFcR and SYK-  
576 NeonGreen (Addgene, Plasmid # 176610) were plated in one well of a 96-well glass  
577 bottom MatriPlate (Brooks, Catalog # MGB096-1-2-LG-L) between 12 and 24 h prior to  
578 the experiment. Cells were then continuously imaged with high intensity light stimulation  
579 for 30 min. Colocalization was determined by a pearsons correlation coefficient for the  
580 same membrane region at the first and last timepoints using the JaCoP plugin in  
581 ImageJ<sup>53</sup>.

582

583 **ICAM-1 protein purification.**

584 ICAM-tagBFP-His<sub>10</sub><sup>54</sup> was expressed in SF9 or HiFive cells using the Bac-to-Bac  
585 baculovirus system as described previously<sup>55</sup>. Insect cell media containing secreted  
586 proteins was harvested 72 h after infection with baculovirus. His10 proteins were  
587 purified by using Ni-NTA agarose (QIAGEN, Catalog # 30230), followed by size  
588 exclusion chromatography using a Superdex 200 10/300 GL column (GE Healthcare,  
589 Catalog # 17517501). The purification buffer was 150 mM NaCl, 50 mM HEPES pH 7.4,  
590 5% glycerol, 2 mM TCEP.

591

592 **Supported lipid bilayer coated beads.**

593 SUV preparation

594 For IgG conjugated beads the following chloroform-suspended lipids were mixed and  
595 desiccated overnight to remove chloroform: 98.8% POPC (Avanti, Catalog # 850457),  
596 1% biotinyl cap PE (Avanti, Catalog # 870273), 0.1% PEG5000-PE (Avanti, Catalog #  
597 880230, and 0.1% atto390-DOPE (ATTO-TEC GmbH, Catalog # AD 390–161) or 0.1%  
598 atto647-DOPE (ATTO-TEC GmbH, Catalog # AD 647–161). The lipid sheets were  
599 resuspended in PBS, pH7.2 (GIBCO, Catalog # 20012050) at 10 mM concentration and  
600 stored under inert nitrogen gas.

601 For ICAM-1 conjugated beads, the following chloroform-suspended lipids were mixed  
602 and desiccated overnight to remove chloroform: 97.8% POPC (Avanti, Catalog #  
603 850457), 2% DGS-NTA (Avanti, Catalog # 790404), 0.1% PEG5000-PE (Avanti,  
604 Catalog # 880230, and 0.1% atto390-DOPE (ATTO-TEC GmbH, Catalog # AD 390–  
605 161). The lipid sheets were resuspended in PBS, pH7.2 (GIBCO, Catalog # 20012050)  
606 and stored under inert gas.

607 For PS beads the following chloroform-suspended lipids were mixed and desiccated  
608 overnight to remove chloroform: 89.8% POPC (Avanti, Catalog # 850457), 10% DOPS  
609 (Avanti, Catalog # 840035), 0.1% PEG5000-PE (Avanti, Catalog # 880230, and 0.1%  
610 atto390-DOPE (ATTO-TEC GmbH, Catalog # AD 390–161). The lipid sheets were  
611 resuspended in PBS, pH7.2 (GIBCO, Catalog # 20012050) and stored under inert gas.

612

613 For all SUVs, the lipids were broken into small unilamellar vesicles via several rounds of  
614 freeze-thaws. The lipids were then stored at -80°C under argon for up to six months. To  
615 remove aggregated lipids, the solution was diluted to 2 mM and filtered through a 0.22  
616 µM filter (Millipore, Catalog # SLLG013SL) immediately prior to use.

617

#### 618 Bead preparation

619 Silica beads with a 4.89 µm diameter (10% solids, Bangs Labs, Catalog # SS05003, Lot  
620 # 13427) were washed with PBS, mixed with 1mM SUVs in PBS and incubated at room  
621 temperature for 30 min with end-over-end mixing to allow for bilayer formation. Beads  
622 were then washed with PBS to remove excess SUVs and incubated in 0.2% casein  
623 (Sigma, Catalog # C5890) in PBS for 15 min before protein coupling (IgG and ICAM-1  
624 beads). For IgG conjugated beads, anti-biotin AlexaFluor647-IgG (Jackson  
625 ImmunoResearch Laboratories Catalog # 200-602-211, Lot # 156182) was added at 1  
626 nM to a 10x dilution of beads (1% solids), unless otherwise indicated. For ICAM-1  
627 conjugated beads, ICAM-1 was added at 10nM. Proteins were coupled to the bilayer for  
628 30 min at room temperature with end-over-end mixing.

629

#### 630 Bead engulfment assay

631 50,000 BMDMs were plated in one well of a 96-well glass bottom MatriPlate (Brooks,  
632 Catalog # MGB096-1-2-LG-L) between 12 and 24 h prior to the experiment.  $\sim 8 \times 10^5$   
633 beads were added to wells and engulfment was allowed to proceed for 15 min.

634

#### 635 Inhibitors

636 For transcription and translation inhibited priming, 10 nM actinomycin D (Cell signaling,  
637 Catalog # 15021s) or 10 µg/ml cycloheximide (Cell signaling, Catalog # 2112s) were  
638 added to cells 7 hours prior to the start of the experiment. For ERK inhibited priming, 0.5  
639 µM PD0325901 (Sigma, Catalog # PZ0162) was added to cells 16 hours prior to the  
640 start of the experiment.

641

#### 642 Microscopy and analysis

643 Images were acquired on a spinning disc confocal microscope (Nikon Ti2-E inverted  
644 microscope with a Yokogawa CSU-W1 spinning disk unit and an Orca Fusion BT scMos  
645 camera) equipped with a 40 × 0.95 NA Plan Apo air and a 100 × 1.49 NA oil immersion  
646 objective. The microscope was controlled using Nikon Elements. Internalized particles  
647 were counted in ImageJ by a blinded analyzer using Blind-Analysis-Tools-1.0 ImageJ  
648 plug in.

649

#### 650 **Bead priming**

651 50,000 BMDMs were plated in 1 well of a 96-well glass bottom plate 12-24 hrs prior to  
652 the start of the experiment. A priming dose of  $\sim 8 \times 10^5$  atto390 beads conjugated to

653 either 1 nM or 0 nM IgG were added to the wells for 15 min. Any unengulfed beads  
654 were washed out 5x with media, then checked with a dissecting microscope to confirm  
655 the majority of engulfed beads had been removed. Then the cells were allowed to  
656 recover for 1 hour.  $\sim 8 \times 10^5$  atto647 beads prepared with the indicated IgG  
657 concentrations were then added to the wells and engulfment was allowed to proceed for  
658 15 min. Cells were dyed with CellTrace CFSE (Thermo, Catalog # C34570) imaged and  
659 the number of atto647 beads engulfed per cell were counted.

660

#### 661 **Raji eating assay.**

662 40,000 BMDMs were plated in 1 well of a 96-well glass bottom plate 24 hrs prior to the  
663 experiment and stimulated with low intensity LITOS illumination 12 hrs prior to the  
664 experiment. Raji cells were dyed with CellTrace Far Red (Thermo, C34572), incubated  
665 with a human-mouse hybrid aCD20 (InvivoGen hcd20-mab10, 5 ng/ml), added to wells  
666 at 40,000 cells per well, and imaged immediately. 25 positions per well were  
667 automatically selected and imaged every 3 min for 10 hrs. Unless otherwise noted, 100  
668 macrophages were randomly selected and scored by a blind analyzer. Phagocytic  
669 macrophages were characterized as BMDMs that engulfed 1 or more whole Raji cell  
670 targets. Trophocytic macrophages were characterized as BMDMs that engulfed portions  
671 of Raji targets. The number of Raji cells engulfed per 100 macrophages was also  
672 counted.

673

#### 674 **Kinetics of engulfment.**

675 BMDMs were plated as described in the bead engulfment assay 12-24 hrs prior to the  
676 experiment and stimulated with low intensity LITOS illumination 1 hr prior to the  
677 experiment. Using ND acquisition in Elements, 2-3 positions per well were manually  
678 selected. Approximately  $4 \times 10^5$  beads were added and phagocytosis was imaged at 20  
679 s intervals through 7 z planes for 15 min. Only beads that bound within the first 12 min  
680 were counted.

681

#### 682 **Receptor labeling and single particle tracking.**

##### 683 Fab generation.

684 Fabs from rat anti-mouse FcR (Cell signaling, 101307) and rabbit anti-rat biotin  
685 conjugated (Invitrogen, 13-4813-85) were generated using the Pierce Fab Preparation  
686 Kit (Thermo, 44985) according to the manufacture's protocol. In brief, antibodies were  
687 run through a Zeba desalting column before cleavage with immobilized papain for 3  
688 hours with end over end mixing and digestion was confirmed via SDS-PAGE. Fab  
689 fragments were then purified using a NAb Protein A column.

690

##### 691 Receptor labeling and imaging.

692 Single FcRs were labeled as previously described<sup>31</sup>. In brief, cells were blocked for 5  
693 min in RPMI supplemented with 5% goat serum. Then, cells were incubated with  
694 primary fab fragments for 10 min in blocking medium. Next, cells were incubated with  
695 biotinylated secondary fab fragments for 10 min. Finally, cells were washed with  
696 blocking media and incubated with streptavidin-conjugated Qdot 655 (Thermo,  
697 Q10123MP) for 4 min and immediately imaged. Images were acquired at 10 fps for 1  
698 min using ND acquisition in Elements on a spinning disc confocal microscope.

699

#### 700 Tracking.

701 Tracks and particle mean jump distance were generated using the trackmate plugin on  
702 ImageJ<sup>56,57</sup>. Tracks that were less than 50 frames or that contained gaps greater than 3  
703 frames were discarded from analysis. Motion types and diffusion coefficients were  
704 determined using moment scaling spectrum analysis using the formula described in  
705 Ewers et al, 2005<sup>31,58-60</sup>.

706

#### 707 **Quantification and statistical analysis.**

708 Statistical analysis was performed in Prism 8 (GraphPad). The statistical test used is  
709 indicated in the relevant figure legend. Sample sizes were predetermined and indicated  
710 in the relevant figure legend.

711

## 712 References

713

- 714 1. Freeman, S.A., and Grinstein, S. (2014). Phagocytosis: Receptors, signal integration, and the  
715 cytoskeleton. *Immunological Reviews* 262, 193–215. 10.1111/imr.12212.
- 716 2. Nimmerjahn, F., and Ravetch, J.V. (2008). Fcγ receptors as regulators of immune responses.  
717 *Nature Reviews Immunology* 8, 34–47. 10.1038/nri2206.
- 718 3. Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten  
719 Hagen, T.L.M., Kubes, P., and van Egmond, M. (2014). Macrophages eliminate circulating  
720 tumor cells after monoclonal antibody therapy. *J Clin Invest* 124, 812–823.  
721 10.1172/JCI66776.
- 722 4. Weiskopf, K., and Weissman, I.L. (2015). Macrophages are critical effectors of antibody  
723 therapies for cancer. *mAbs* 7, 303–310. 10.1080/19420862.2015.1011450.
- 724 5. Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Rooijen, N.V., and Bousso, P.  
725 (2013). The mechanism of anti-CD20-mediated B cell depletion revealed by intravital  
726 imaging. *J Clin Invest* 123, 5098–5103. 10.1172/JCI70972.
- 727 6. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., and Tedder,  
728 T.F. (2004). The innate mononuclear phagocyte network depletes B lymphocytes through Fc  
729 receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. *Journal of*  
730 *Experimental Medicine* 199, 1659–1669. 10.1084/jem.20040119.
- 731 7. Watanabe, M., Wallace, P.K., Keler, T., Deo, Y.M., Akewanlop, C., and Hayes, D.F. (1999).  
732 Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular  
733 cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. *Breast*  
734 *Cancer Research and Treatment* 53, 199–207. 10.1023/A:1006145507567.
- 735 8. Chen, X., Song, X., Li, K., and Zhang, T. (2019). FcγR-Binding Is an Important Functional  
736 Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. *Frontiers in*  
737 *Immunology* 10, 292. 10.3389/fimmu.2019.00292.
- 738 9. Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A.J., and Ravetch, J.V. (2015).  
739 FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. *Cancer*  
740 *Cell* 28.
- 741 10. Zhang, Y., Hoppe, A.D., and Swanson, J.A. (2010). Coordination of Fc receptor  
742 signaling regulates cellular commitment to phagocytosis. *Proceedings of the National*  
743 *Academy of Sciences* 107, 19332–19337. 10.1073/pnas.1008248107.
- 744 11. Gottschalk, R.A., Martins, A.J., Angermann, B.R., Dutta, B., Ng, C.E., Uderhardt, S.,  
745 Tsang, J.S., Fraser, I.D.C., Meier-Schellersheim, M., and Germain, R.N. (2016). Distinct NF-  
746 κB and MAPK Activation Thresholds Uncouple Steady-State Microbe Sensing from Anti-  
747 pathogen Inflammatory Responses. *Cell Systems* 2, 378–390. 10.1016/j.cels.2016.04.016.
- 748 12. Bettadapur, A., Miller, H.W., and Ralston, K.S. (2020). Biting off what can be chewed:  
749 Trogocytosis in health, infection, and disease. *Infection and Immunity* 88. 10.1128/IAI.00930-  
750 19/ASSET/50880292-BFB8-40CC-A318-88FA45997A88/ASSETS/GRAPHIC/IAI.00930-19-  
751 F0006.JPEG.
- 752 13. Velmurugan, R., Challa, D.K., Ram, S., Ober, R.J., and Ward, E.S. (2016). Macrophage-  
753 Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. *Molecular*  
754 *Cancer Therapeutics* 15, 1879–1889. 10.1158/1535-7163.MCT-15-0335.
- 755 14. Beum, P.V., Peek, E.M., Lindorfer, M.A., Beurskens, F.J., Engelberts, P.J., Parren,  
756 P.W.H.I., van de Winkel, J.G.J., and Taylor, R.P. (2011). Loss of CD20 and bound CD20  
757 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc  
758 receptor-expressing effector cells than direct internalization by the B cells. *Journal of*  
759 *immunology* (Baltimore, Md. □: 1950) 187, 3438–3447. 10.4049/JIMMUNOL.1101189.
- 760 15. Pham, T., Mero, P., and Booth, J.W. (2011). Dynamics of Macrophage Trogocytosis of  
761 Rituximab-Coated B Cells. *PLoS One* 6, e14498. 10.1371/journal.pone.0014498.


- 762 16. Weavers, H., Evans, I.R., Martin, P., and Wood, W. (2016). Corpse Engulfment  
763 Generates a Molecular Memory that Primes the Macrophage Inflammatory Response. *Cell*  
764 165, 1658–1671. 10.1016/j.cell.2016.04.049.
- 765 17. Sharma, P., Vijaykumar, A., Raghavan, J.V., Rananaware, S.R., Alakesh, A., Bodele, J.,  
766 Rehman, J.U., Shukla, S., Wagde, V., Nadig, S., et al. (2022). Particle uptake driven  
767 phagocytosis in macrophages and neutrophils enhances bacterial clearance. *Journal of*  
768 *Controlled Release* 343, 131–141. 10.1016/j.jconrel.2022.01.030.
- 769 18. Pinney, J.J., Rivera-Escalera, F., Chu, C.C., Whitehead, H.E., Vandermeid, K.R.,  
770 Nelson, A.M., Barbeau, M.C., Zent, C.S., and Elliott, M.R. (2020). Macrophage hypophagia  
771 as a mechanism of innate immune exhaustion in mAb-induced cell clearance. *Blood* 136,  
772 2065–2079. 10.1182/BLOOD.2020005571.
- 773 19. Zent, C.S., and Elliott, M.R. (2017). Maxed out macs: physiologic cell clearance as a  
774 function of macrophage phagocytic capacity. *The FEBS Journal* 284, 1021–1039.  
775 10.1111/febs.13961.
- 776 20. Goodridge, H.S., Underhill, D.M., and Touret, N. (2012). Mechanisms of Fc Receptor  
777 and Dectin-1 Activation for Phagocytosis. *Traffic* 13, 1062–1071. 10.1111/j.1600-  
778 0854.2012.01382.x.
- 779 21. Kern, N., Dong, R., Douglas, S.M., Vale, R.D., and Morrissey, M.A. (2021). Tight  
780 nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis. *eLife* 10.  
781 10.7554/eLife.68311.
- 782 22. Sobota, A., Strzelecka-Kiliszek, A., Gładkowska, E., Yoshida, K., Mrozińska, K., and  
783 Kwiatkowska, K. (2005). Binding of IgG-Opsonized Particles to FcγR Is an Active Stage of  
784 Phagocytosis That Involves Receptor Clustering and Phosphorylation. *The Journal of*  
785 *Immunology* 175, 4450–4457. 10.4049/jimmunol.175.7.4450.
- 786 23. Taslimi, A., Vrana, J.D., Chen, D., Borinskaya, S., Mayer, B.J., Kennedy, M.J., and  
787 Tucker, C.L. (2014). An optimized optogenetic clustering tool for probing protein interaction  
788 and function. *Nat Commun* 5, 4925. 10.1038/ncomms5925.
- 789 24. Springer, T.A., and Dustin, M.L. (2012). Integrin inside-out signaling and the  
790 immunological synapse. *Current Opinion in Cell Biology* 24, 107–115.  
791 10.1016/j.ceb.2011.10.004.
- 792 25. Morrissey, M.A., Kern, N., and Vale, R.D. (2020). CD47 Ligation Repositions the  
793 Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis. *Immunity* 53,  
794 290-302.e6. 10.1016/j.immuni.2020.07.008.
- 795 26. Vorselen, D., Kamber, R.A., Labitigan, R.L.D., Loon, A.P. van, Peterman, E., Delgado,  
796 M.K., Lin, S., Rasmussen, J.P., Bassik, M.C., and Theriot, J.A. (2022). Cell surface receptors  
797 TREM2, CD14 and integrin αMβ2 drive sinking engulfment in phosphatidylserine-mediated  
798 phagocytosis. Preprint at bioRxiv, 10.1101/2022.07.30.502145 10.1101/2022.07.30.502145.
- 799 27. Williamson, A.P., and Vale, R.D. (2018). Spatial control of Draper receptor signaling  
800 initiates apoptotic cell engulfment. *J Cell Biol* 217, 3977–3992. 10.1083/jcb.201711175.
- 801 28. Williams, M.E., Densmore, J.J., Pawluczakowycz, A.W., Beum, P.V., Kennedy, A.D.,  
802 Lindorfer, M.A., Hamil, S.H., Eggleton, J.C., and Taylor, R.P. (2006). Thrice-Weekly Low-  
803 Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in  
804 Chronic Lymphocytic Leukemia1. *The Journal of Immunology* 177, 7435–7443.  
805 10.4049/jimmunol.177.10.7435.
- 806 29. Freeman, S.A., Vega, A., Riedl, M., Collins, R.F., Ostrowski, P.P., Woods, E.C.,  
807 Bertozzi, C.R., Tammi, M.I., Lidke, D.S., Johnson, P., et al. (2018). Transmembrane Pickets  
808 Connect Cyto- and Pericellular Skeletons Forming Barriers to Receptor Engagement. *Cell*  
809 172, 305-317.e10. 10.1016/j.cell.2017.12.023.
- 810 30. Kusumi, A., Fujiwara, T.K., Chadda, R., Xie, M., Tsunoyama, T.A., Kalay, Z., Kasai,  
811 R.S., and Suzuki, K.G.N. (2012). Dynamic Organizing Principles of the Plasma Membrane  
812 that Regulate Signal Transduction: Commemorating the Fortieth Anniversary of Singer and

- 813 Nicolson's Fluid-Mosaic Model. *Annual Review of Cell and Developmental Biology* 28, 215–  
814 250. [10.1146/annurev-cellbio-100809-151736](https://doi.org/10.1146/annurev-cellbio-100809-151736).
- 815 31. Jaumouillé, V., Farkash, Y., Jaqaman, K., Das, R., Lowell, C.A., and Grinstein, S.  
816 (2014). Actin Cytoskeleton Reorganization by Syk Regulates Fcγ Receptor Responsiveness  
817 by Increasing Its Lateral Mobility and Clustering. *Developmental Cell* 29, 534–546.  
818 [10.1016/j.devcel.2014.04.031](https://doi.org/10.1016/j.devcel.2014.04.031).
- 819 32. Andrews, N.L., Lidke, K.A., Pfeiffer, J.R., Burns, A.R., Wilson, B.S., Oliver, J.M., and  
820 Lidke, D.S. (2008). Actin restricts FcεRI diffusion and facilitates antigen-induced  
821 receptor immobilization. *Nat Cell Biol* 10, 955–963. [10.1038/ncb1755](https://doi.org/10.1038/ncb1755).
- 822 33. Duchemin, A.M., Ernst, L.K., and Anderson, C.L. (1994). Clustering of the high affinity Fc  
823 receptor for immunoglobulin G (Fc gamma RI) results in phosphorylation of its associated  
824 gamma-chain. *J Biol Chem* 269, 12111–12117.
- 825 34. Lin, J., Kurilova, S., Scott, B.L., Bosworth, E., Iverson, B.E., Bailey, E.M., and Hoppe,  
826 A.D. (2016). TIRF imaging of Fc gamma receptor microclusters dynamics and signaling on  
827 macrophages during frustrated phagocytosis. *BMC Immunology* 17, 5. [10.1186/s12865-016-0143-2](https://doi.org/10.1186/s12865-016-0143-2).
- 829 35. Goodridge, H.S., Reyes, C.N., Becker, C.A., Katsumoto, T.R., Ma, J., Wolf, A.J., Bose,  
830 N., Chan, A.S.H., Magee, A.S., Danielson, M.E., et al. (2011). Activation of the innate  
831 immune receptor Dectin-1 upon formation of a 'phagocytic synapse.' *Nature* 472, 471–475.  
832 [10.1038/nature10071](https://doi.org/10.1038/nature10071).
- 833 36. James, J.R., and Vale, R.D. (2012). Biophysical mechanism of T-cell receptor triggering  
834 in a reconstituted system. *Nature* 487, 64–69. [10.1038/nature11220](https://doi.org/10.1038/nature11220).
- 835 37. Bakalar, M.H., Joffe, A.M., Schmid, E.M., Son, S., Podolski, M., and Correspondence,  
836 D.A.F. (2018). Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-  
837 Opsonized Targets. *Cell* 174, 131–142. [10.1016/j.cell.2018.05.059](https://doi.org/10.1016/j.cell.2018.05.059).
- 838 38. Freeman, S.A., Goyette, J., Furuya, W., Woods, E.C., Bertozzi, C.R., Bergmeier, W.,  
839 Hinz, B., Van Der Merwe, P.A., Das, R., and Grinstein, S. (2016). Integrins Form an  
840 Expanding Diffusional Barrier that Coordinates Phagocytosis. *Cell* 164, 128–140.  
841 [10.1016/j.cell.2015.11.048](https://doi.org/10.1016/j.cell.2015.11.048).
- 842 39. Davis, S.J., and van der Merwe, P.A. (2006). The kinetic-segregation model: TCR  
843 triggering and beyond. *Nature Immunology* 7, 803–809. [10.1038/ni1369](https://doi.org/10.1038/ni1369).
- 844 40. Shelby, S.A., and Veatch, S.L. (2023). The Membrane Phase Transition Gives Rise to  
845 Responsive Plasma Membrane Structure and Function. *Cold Spring Harb Perspect Biol*,  
846 a041395. [10.1101/cshperspect.a041395](https://doi.org/10.1101/cshperspect.a041395).
- 847 41. Stone, M.B., Shelby, S.A., Níñez, M.F., Wissner, K., and Veatch, S.L. (2017). Protein  
848 sorting by lipid phase-like domains supports emergent signaling function in b lymphocyte  
849 plasma membranes. *eLife* 6, 1–33. [10.7554/eLife.19891](https://doi.org/10.7554/eLife.19891).
- 850 42. Jaumouillé, V., Grinstein, S., Jaumouillé, V., and Grinstein, S. (2011). Receptor mobility,  
851 the cytoskeleton, and particle binding during phagocytosis. *Current Opinion in Cell Biology*  
852 23, 22–29. [10.1016/j.ceb.2010.10.006](https://doi.org/10.1016/j.ceb.2010.10.006).
- 853 43. Netea, M.G., Domínguez-Andrés, J., Barreiro, L.B., Chavakis, T., Divangahi, M., Fuchs,  
854 E., Joosten, L.A.B., van der Meer, J.W.M., Mhlanga, M.M., Mulder, W.J.M., et al. (2020).  
855 Defining trained immunity and its role in health and disease. *Nat Rev Immunol* 20, 375–388.  
856 [10.1038/s41577-020-0285-6](https://doi.org/10.1038/s41577-020-0285-6).
- 857 44. Tehrani, S.S.H., Kogan, A., Mikulski, P., and Jansen, L.E.T. (2023). Remembering foods  
858 and foes: emerging principles of transcriptional memory. *Cell Death Differ*, 1–11.  
859 [10.1038/s41418-023-01200-6](https://doi.org/10.1038/s41418-023-01200-6).
- 860 45. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F.,  
861 Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. (2013). Fc-dependent depletion of  
862 tumor-infiltrating regulatory t cells co-defines the efficacy of anti-CTLA-4 therapy against  
863 melanoma. *Journal of Experimental Medicine* 210, 1695–1710. [10.1084/jem.20130579](https://doi.org/10.1084/jem.20130579).

- 864 46. Morrissey, M.A., Williamson, A.P., Steinbach, A.M., Roberts, E.W., Kern, N., Headley,  
865 M.B., and Vale, R.D. (2018). Chimeric antigen receptors that trigger phagocytosis. *eLife* 7,  
866 e36688. 10.7554/eLife.36688.
- 867 47. Klichinsky, M., Ruella, M., Shestova, O., Lu, X.M., Best, A., Zeeman, M., Schmierer, M.,  
868 Gabrusiewicz, K., Anderson, N.R., Petty, N.E., et al. (2020). Human chimeric antigen  
869 receptor macrophages for cancer immunotherapy. *Nature Biotechnology* 38, 947–953.  
870 10.1038/s41587-020-0462-y.
- 871 48. Sloas, C., Gill, S., and Klichinsky, M. (2021). Engineered CAR-Macrophages as  
872 Adoptive Immunotherapies for Solid Tumors. *Front Immunol* 12, 783305.  
873 10.3389/fimmu.2021.783305.
- 874 49. Wang, S., Yang, Y., Ma, P., Zha, Y., Zhang, J., Lei, A., and Li, N. (2022). CAR-  
875 macrophage: An extensive immune enhancer to fight cancer. *eBioMedicine* 76.  
876 10.1016/j.ebiom.2022.103873.
- 877 50. Weischenfeldt, J., and Porse, B. (2008). Bone Marrow-Derived Macrophages (BMM):  
878 Isolation and Applications. *Cold Spring Harb Protoc* 2008, pdb.prot5080.  
879 10.1101/pdb.prot5080.
- 880 51. Stewart, S.A., Dykxhoorn, D.M., Palliser, D., Mizuno, H., Yu, E.Y., An, D.S., Sabatini,  
881 D.M., Chen, I.S.Y., Hahn, W.C., Sharp, P.A., et al. (2003). Lentivirus-delivered stable gene  
882 silencing by RNAi in primary cells. *RNA* 9, 493–501. 10.1261/rna.2192803.
- 883 52. Höhener, T.C., Landolt, A.E., Dessauges, C., Hinderling, L., Gagliardi, P.A., and Pertz,  
884 O. (2022). LITOS: a versatile LED illumination tool for optogenetic stimulation. *Sci Rep* 12,  
885 13139. 10.1038/s41598-022-17312-x.
- 886 53. Bolte, S., and Cordelières, F.P. (2006). A guided tour into subcellular colocalization  
887 analysis in light microscopy. *Journal of Microscopy* 224, 213–232. 10.1111/j.1365-  
888 2818.2006.01706.x.
- 889 54. O'Donoghue, G.P., Pielak, R.M., Smoligovets, A.A., Lin, J.J., and Groves, J.T. (2013).  
890 Direct single molecule measurement of TCR triggering by agonist pMHC in living primary T  
891 cells. *eLife* 2, e00778. 10.7554/eLife.00778.
- 892 55. Hui, E., and Vale, R.D. (2014). In vitro membrane reconstitution of the T-cell receptor  
893 proximal signaling network. *Nat Struct Mol Biol* 21, 133–142. 10.1038/nsmb.2762.
- 894 56. Ershov, D., Phan, M.-S., Pylvänäinen, J.W., Rigaud, S.U., Le Blanc, L., Charles-Orszag,  
895 A., Conway, J.R.W., Laine, R.F., Roy, N.H., Bonazzi, D., et al. (2022). TrackMate 7:  
896 integrating state-of-the-art segmentation algorithms into tracking pipelines. *Nat Methods* 19,  
897 829–832. 10.1038/s41592-022-01507-1.
- 898 57. Tinevez, J.-Y., Perry, N., Schindelin, J., Hoopes, G.M., Reynolds, G.D., Laplantine, E.,  
899 Bednarek, S.Y., Shorte, S.L., and Eliceiri, K.W. (2017). TrackMate: An open and extensible  
900 platform for single-particle tracking. *Methods* 115, 80–90. 10.1016/j.ymeth.2016.09.016.
- 901 58. Ferrari, R., Manfroï, A.J., and Young, W.R. (2001). Strongly and weakly self-similar  
902 diffusion. *Physica D: Nonlinear Phenomena* 154, 111–137. 10.1016/S0167-2789(01)00234-2.
- 903 59. Ewers, H., Smith, A.E., Sbalzarini, I.F., Lilie, H., Koumoutsakos, P., and Helenius, A.  
904 (2005). Single-particle tracking of murine polyoma virus-like particles on live cells and  
905 artificial membranes. *Proceedings of the National Academy of Sciences* 102, 15110–15115.  
906 10.1073/pnas.0504407102.
- 907 60. Jaqaman, K., Kuwata, H., Touret, N., Collins, R., Trimble, W.S., Danuser, G., and  
908 Grinstein, S. (2011). Cytoskeletal control of CD36 diffusion promotes its receptor and  
909 signaling function. *Cell* 146, 593–606. 10.1016/j.cell.2011.06.049.



Figure 1: optogenetic FcR controls phagocytosis



**Figure 2: Prior FcR activation specifically enhances macrophage sensitivity to IgG**







Figure 3: Primed macrophages phagocytose more antibody opsonized cancer cells



**C** % phagocytic BMDMs



**D** # Rajis engulfed



**E** % trogocytic BMDMs






Figure 4: FcR mediated priming occurs via a short and long term mechanism



**Figure 5: Initiation of phagocytosis is faster and the probability of completing phagocytosis is higher in primed macrophages**



**Figure 6: priming increases FcR mobility**